PRESS RELEASE

Exercise of Share Options and Total Voting Rights

Guildford, UK - 1 November 2022: Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company") announces that, following an exercise of share options, application has been made to AIM for the admission of 70,000 new ordinary shares of 1p each in the capital of the Company (the "New Ordinary Shares").

Admission to trading on AIM of the New Ordinary Shares ("Admission") is expected to occur on 4 November 2022.  Following Admission, the New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares.

Following Admission, the total number of ordinary shares with voting rights in issue will be 50,085,405. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

ENDS

Enquiries:

Ergomed plc                                                                           Tel: +44 (0) 1483 402 975

Dr Miroslav Reljanović (Executive Chairman)      

Richard Barfield (Chief Financial Officer)           

Keith Byrne (Senior Vice-President, Capital Markets & Strategy)

Numis                                                                                      Tel: +44 (0) 20 7260 1000

Freddie Barnfield / Euan Brown (Nominated Adviser)      

James Black (Broker)   

Peel Hunt LLP                                                                         Tel: +44 (0) 20 7418 8900

James Steel / Dr Christopher Golden

Consilium Strategic Communications                                 Tel: +44 (0) 20 3709 5700

Chris Gardner / Matthew Neal                                                  ergomed@consilium-comms.com

Angela Gray

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO) and mission-critical regulatory compliance and consulting services under the ADAMAS brand. For further information, visit: http://ergomedplc.com.